On November 2nd, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as “Yingling Pharmaceuticalâ€) announced the “Deepening of 2018-2021†signed with China Resources Pharmaceutical Commercial Group Co., Ltd. (hereinafter referred to as “China Resources Medicineâ€). The framework agreement for the strategic partnership of industry and commerce, the two sides will play their respective advantages and integrate their own resources to achieve mutual benefit and win-win.
Specifically, at the level of information resource sharing, Yiling Pharmaceutical will provide upstream market information for pharmaceutical production to China Resources Pharmaceutical, and each subsidiary of China Resources Pharmaceutical will provide the necessary product distribution flow and terminal medical information to Yiling Pharmaceutical for free, effective guidance and Assisting Yiling Pharmaceutical to develop the primary medical terminal market.
In terms of business cooperation, the sales organization of Yiling Pharmaceutical Co., Ltd. and all subsidiaries of China Resources Medical Co., Ltd. are fully integrated, designated personnel to connect, and set work goals and plans. Comprehensive cooperation in the general and new drug markets of hospital distribution, primary medical institution sales and logistics distribution.
Not long ago, Yiling Pharmaceutical released the third quarter report this year. From July to September, Yiling Pharmaceutical achieved revenue of 1.126 billion yuan, up 38.17% year-on-year; net profit attributable to shareholders of listed companies was 114 million yuan, up 3.3% year-on-year. From the beginning of the year to the end of the third quarter, the cumulative revenue of Yiling Pharmaceutical was 3.826 billion yuan, up 25.05% year-on-year; and the net profit attributable to shareholders of listed companies was 562 million yuan, up 25.01 year-on-year. %.
In response to the increase in the net profit of Q3, which was significantly lower than the increase in revenue, Yiling Pharmaceutical said that during the reporting period, the sales of the main products of Yiling Pharmaceuticals showed a rebound trend, which in turn affected the revenue year-on-year. growth of. However, due to the increase in the price of some medicinal materials and the combined effect of the product delivery structure, the increase in the cost rate caused the increase in net profit during the reporting period not to keep pace with income.
Recently, Yiling Pharmaceutical's leading products, Qiangqiangxin Capsule and Tongxinluo Capsule, were included in the "Guidelines for the Diagnosis and Treatment of Heart Failure in China 2018" and the "Consensus of Integrative Medicine for Chronic Cerebral Ischemia". According to the announcement, Qiangxin Capsule's 2017 annual revenue was 452 million yuan, accounting for 11.10% of the company's revenue; from January to September 2018, revenue was 377 million yuan, accounting for 9.87 percent of the company's revenue. %. The performance of another leading product is more prominent. In 2017, Tongxinluo Capsule revenue reached 1.019 billion yuan, accounting for 25.04% of the company's revenue; from January to September 2018, the cumulative revenue of this product was 8 1.4 billion yuan, accounting for 21.31% of the company's revenue.
As the sales of products grow, how to ensure cost control while developing in the terminal market has become a problem that Lingling Pharmaceuticals has to face. The cooperation with China Resources Pharmaceuticals can be seen as a corresponding policy of Yiling Pharmaceutical to a certain extent.
China Resources Medicine and Sinopharm, Shanghai Pharmaceuticals and Kyushu Tong said that the four giants in China's pharmaceutical circulation sector have their own layouts in the pharmaceutical industry, commercial distribution and retail. In the first half of 2018, China Resources Pharmaceutical ranked second with revenue of 81.351 billion yuan and growth rate of 13.30%. Among them, the distribution business revenue was 67.512 billion yuan.
In the first half of this year, China Resources Pharmaceutical accelerated the network layout in the blank provinces in the west. As of the end of the reporting period, its medical fee distribution network has covered 27 provinces, municipalities and autonomous regions. At the same time, the downstream terminal market of China Resources Pharmaceuticals is also expanding rapidly. According to public data, China Resources Pharmaceutical's customers include 5,857 second- and third-level hospitals, 38,954 primary medical institutions, and 28,916 retail pharmacies. Compared with the 2017 data, the growth of primary medical institutions is the most prominent, reaching 6,790.
In recent years, the promotion of the new medical reform policy has also prompted grassroots medical service institutions to be constantly relied on by various companies. Benefiting from the increasingly comprehensive development of the primary health care system and the in-depth development of the grading diagnosis and treatment policy, the growth rate of major categories in the future will exceed the hospital terminal. How to develop the primary medical market has become a difficult problem for major pharmaceutical companies to think about.
The cooperation announcement revealed that Yiling Pharmaceutical will continue to cooperate with various regional subsidiaries of China Resources Pharmaceuticals, and cooperate with local medical associations and pharmaceutical associations to carry out various promotional activities to promote strategic cooperation between the two sides in the development of pharmaceutical markets at all levels. Ling Pharmaceutical's product market coverage.
plastic medical collectors
Guangdong Widinlsa International Co.Ltd , https://www.widinlsamachine.com